Human tetherin is a host restriction factor that inhibits replication of enveloped viruses by blocking viral release. Tetherin has an unusual topology that includes an N-terminal cytoplasmic tail, a single transmembrane domain, an extracellular domain, and a C-terminal glycosylphosphatidylinositol anchor. Tetherin is not well conserved across species, so it inhibits viral replication in a species-specific manner. Thus, studies of tetherin activities from different species provide an important tool for understanding its antiviral mechanism. Here, we report cloning of equine tetherin and characterization of its antiviral activity. Equine tetherin shares 53%, 40%, 36%, and 34% amino acid sequence identity with feline, human, simian, and murine tetherins, respectively. Like the feline tetherin, equine tetherin has a shorter N-terminal domain than human tetherin. Equine tetherin is localized on the cell surface and strongly blocks human immunodeficiency virus type 1 (HIV-1), simian immunodeficiency virus (SIV), and equine infectious anemia virus (EIAV) release from virus-producing cells. The antiviral activity of equine tetherin is neutralized by EIAV envelope protein, but not by the HIV-1 accessory protein Vpu, which is a human tetherin antagonist, and EIAV envelope protein does not counteract human tetherin. These results shed new light on our understanding of the species-specific tetherin antiviral mechanism.
T etherin (also referred to as HM1.24, BST-2, or CD317) is a type II single-pass transmembrane protein. Human tetherin (huTHN) was first identified as a cellular restriction factor that blocks human immunodeficiency virus type 1 (HIV-1) particle release from infected cells in the absence of the HIV-1 accessory protein Vpu (1) . Later, it was found that human tetherin has very broad antiviral activities, which also target many other enveloped viruses, including retroviruses, filoviruses, arenaviruses, paramyxoviruses, herpesviruses, and rhabdoviruses (2) (3) (4) (5) (6) (7) (8) (9) . Human tetherin orthologs have been isolated from several other species, including monkey, cat, pig, mouse, cattle, and sheep, which all show similar antiviral activities (10) (11) (12) (13) (14) (15) (16) (17) .
Tetherin has an unusual topology, which consists of an N-terminal cytoplasmic tail (CT), a single transmembrane domain, an extracellular domain, and a C-terminal glycosylphosphatidylinositol (GPI) membrane anchor (18) . The extracellular coiledcoil domain promotes dimerization of adjacent tetherin molecules with disulfide links. This topology is rare and is shared only with an isoform of the prion protein (19) . Accordingly, these structural features together determine tetherin's antiviral function. During viral infection, tetherins on the cell surface and viral envelope can prevent virion release either by direct cross-linking or by the formation of dimers between adjacent coiled-coil domains (20) . Tetherin is constitutively expressed in mature B cells, some cancer cell lines, bone marrow stromal cells, monocyte-derived macrophages, and plasmacytoid dendritic cells, and its expression can be induced by type I and II interferon (IFN) treatment (21) (22) (23) (24) (25) (26) (27) (28) . Thus, tetherin may play a fundamental role in the initiation and perpetuation of a virus-specific immune response. Some viruses encode proteins to counteract tetherin. The known tetherin antagonists include the Vpu protein of HIV-1; the envelope proteins of HIV-2, simian immunodeficiency virus from tantalus monkeys (SIVtan), feline immunodeficiency virus (FIV), and Ebola virus; the Nef protein of SIV; and the K5 protein of the human herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV). These viral proteins antagonize the antiviral activity of tetherin by different mechanisms (1, 2, 16, (29) (30) (31) (32) . Equine infectious anemia virus (EIAV) is a macrophage-tropic lentivirus that causes a persistent infection characterized by recurring viremia, fever, thrombocytopenia, and wasting symptoms (33, 34) . EIAV shares genetic and structural similarity with HIV, SIV, and FIV. In addition to the structural proteins encoded by gag, pol, and env, EIAV encodes three accessory proteins: Tat, Rev, and S2, making EIAV the least complex lentivirus. EIAV infection induces a reproducible clinical disease course, which provides a useful model for comparative study of restriction factors that are involved in resistance to lentiviral infection and a very useful system for lentivirus vaccine development.
Although tetherins from many different species have been well characterized as potent antiretroviral factors, whether equine cells encode an ortholog of tetherin and the interaction between equine tetherin (eqTHN) and EIAV or other retroviruses remain unknown. In this study, we isolated the equine tetherin gene and investigated its antiviral activity and how this activity is counteracted by EIAV. We found that equine tetherin has very broad antiviral activity and that its activity is only neutralized by the EIAV envelope protein.
MATERIALS AND METHODS
Identification and cloning of the equine tetherin gene. Based on the genome data for Equus caballus, an equine tetherin gene was identified on the chromosome 21 genomic scaffold of Equus caballus breed thoroughbred, EquCab2.0 scaffold_73 (GenBank accession no. NW_001867390.1). Oligonucleotide primers were synthesized corresponding to the predicted start (forward primer 5=-ATGGGGGACCACAGGCTGCTGAGAT-3=) and stop (reverse primer 5=-TCAGGCCTGCAGATCCCAGAGGCCC-3=) codons of equine tetherin. Total RNA was extracted from equine macrophages using TRIzol reagent (Invitrogen) and subjected to reverse transcription (RT)-PCR. The amplified fragments were cloned into pEFFlag-HA, which was constructed from pEF4/myc-His B (Invitrogen) to express a protein fused to a tandem FLAG-HA (hemagglutinin) tag at the N terminus. The expression plasmid for equine tetherin was named pEFeqTHN. The truncated forms of equine tetherin lacking the putative CT or putative GPI anchor were also generated by RT-PCR using total RNA from equine macrophages. To determine the initiation site of equine tetherin and to identify the regulatory elements in the tetherin promoter region, 5= rapid amplification of cDNA ends (RACE) was performed using a 5=-Full RACE Core Set (TaKaRa). Total RNA extracted from equine macrophages was used as a PCR template. The PCR product was cloned into the pMD18-T vector and subsequently sequenced.
Plasmids. Human (huTHN) and macaque (macTHN) tetherin genes were cloned into the pEF-Flag-HA vector. The pcDNA-Vphu vector, which encodes a human codon-optimized form of NL4-3 Vpu (Vphu), was kindly provided by Klaus Strebel (NIH). This vpu gene was subsequently cloned into a pcDNA3.1 (ϩ) vector (Invitrogen) that has two HA tags at the C terminus. The pNL-r-HSAS HIV-1 proviral construct was obtained from Beth Jamieson and Jerome Zack through the NIH AIDS Reagent Program. The SIVmac239 proviral vector pBR239E was kindly provided by Toshiaki Kodama. To create an Env and Nef deletion pBR239E (pBR239E ⌬ E ⌬ N), the env gene was first inactivated by blunting a HindIII site; then, the nef gene was inactivated by swapping with the NheI/EcoRI fragment from p239SpE3=, which contains a premature stop codon in the nef gene region and was also obtained from the NIH AIDS Reagent Program. The pLG3-8 vector expresses the full-length EIAV proviral genome of the EIAV FDDV12 strain. Using this construct as a template, the EIAV gag-pol gene was amplified and inserted into the VR-1012 vector (a gift kindly provided by Xiaofang Yu) by EcoRI and NotI digestion. The EIAV S2 gene was expressed with an N-terminal green fluorescent protein (GFP) tag in the pEGFP-C1 vector (BD Biosciences Clontech). The EIAV rev and env genes were amplified from pLG3-8 and cloned into the pcDNA3.1 mammalian expression vector (Invitrogen).
Cells and transfection. Human embryonic kidney (HEK) 293T cells, equine dermal cells, equine vascular endothelial cells, and HeLa cells were cultured at 37°C in a 5% CO 2 incubator in Dulbecco's modified Eagle's medium (Gibco, Invitrogen) supplemented with 10% fetal bovine serum and penicillin/streptomycin. These cells were transfected either by the calcium-phosphate method or with Lipofectamine 2000 reagent (Invitrogen), following the manufacturer's instructions. Equine primary macrophages were maintained in RPMI 1640, supplemented with 10% horse serum and 30% fetal bovine serum.
Measurement of tetherin expression by real-time PCR. Cells were treated for 24 h with or without 1,000 units/ml alpha interferon (IFN-␣) (Kingfisher Biotech), and the total RNA was extracted as described above. One hundred nanograms of total RNA was subjected to reverse transcription using SuperScript II reverse transcriptase and oligo(dT) [12] [13] [14] [15] [16] [17] [18] as a primer (Invitrogen). Synthesized cDNAs were then subjected to real-time PCR using a SYBR green Master Mix kit (Invitrogen) according to the manufacturer's protocols. Real-time RT-PCR was performed using the tetherin primers 5=-GTGGTGGTGTTTCTGCTTGTG-3= (forward) and 5=-GTTGCGACACTCCTGCTCTG-3= (reverse) and the ␤-actin primers 5=-ACGGCATCGTCACCAACTG-3= (forward) and 5=-CAAACATGAT CTGGGTCATCTTCTC-3= (reverse).
Virion release and Western blotting. To produce virus-like particles (VLPs), a total of 1 ϫ 10 6 293T cells cultured in six-well plates were transfected with 5 g of EIAV Gag Pol expression vector, pNL-r-HSAS, or pBR239E and 0.1 to 2 g of equine, human, or macaque tetherin expression vectors. The proper amount of pEF-Flag-HA empty vector (Invitrogen) was used in the transfection as a control DNA. At 48 h posttransfection, the culture supernatants were harvested and the cells were lysed in buffer containing 100 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM EDTA, and 1% Triton X-100. The supernatants were clarified by low-speed centrifugation, and the released VLPs were collected by centrifugation at 20,000 ϫ g for 2 h. Both viral lysates and cell lysates were separated on 12% gels by SDS-polyacrylamide gel electrophoresis (PAGE). The separated proteins were then transferred onto nitrocellulose membranes and blocked with 5% dried milk in phosphate-buffered saline (PBS) containing 0.1% (vol/vol) Tween 20 for 2 h at room temperature. Membranes were incubated for 2 h with the appropriate primary antibodies, which included a monoclonal anti-Flag antibody (Sigma), a mouse anti-HA antibody (Sigma), anti-EIAV equine serum, anti-HIV-1 p24 monoclonal antibody, anti-SIV p27 monoclonal antibody, and anti-actin antibody (Sigma). The membranes were washed three times with Tris-buffered saline with Tween 20 (TBST) for 10 min each time and then incubated with Alexa Fluor 800-labeled goat anti-mouse IgG or goat anti-horse secondary antibody (Odyssey) for 1 h at room temperature. Specific proteins were detected and quantified using the Odyssey system (Li-Cor).
Coimmunoprecipitation assay. 293T cells were transfected with 1 g of EIAV Env expression vector and 1 g eqTHN-glutathione S-transferase (GST) or huTHN-GST. After 48 h, the cells were lysed in a buffer comprising 100 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM EDTA, and 1% Triton X-100 and then incubated with glutathione-Sepharose beads. The bead-associated proteins were analyzed by Western blotting with an anti-V5 antibody and an anti-EIAV antibody, as described above.
Confocal microscopy. HEK 293T cells grown on glass coverslips were transiently transfected with appropriate tetherin and EIAV Gag Pol expression constructs, employing the Lipofectamine 2000 reagent (Invitrogen). The cells were then fixed with 4% paraformaldehyde-PBS and permeabilized for 10 min in 0.1% Triton X-100 -PBS. The cells were incubated with anti-HA antibody for detection of tetherin or an anti-EIAV antiserum, followed by staining using secondary antibodies conjugated with fluorescein isothiocyanate (FITC) or tetramethyl rhodamine isocyanate (TRITC) (Sigma). After being mounted on slides using AntiFade-4 6-diamidino-2-phenylindole (DAPI) mounting solution (Sigma), the cells were visualized with a Leica DM-IRE2 confocal microscope.
RESULTS
Characterization of the equine tetherin gene. After screening the equine genome, a genomic sequence with significant homology to tetherin was identified on chromosome 21. To clone this gene, primers were designed, and a 498-bp fragment was amplified from equine macrophages by RT-PCR, which was confirmed as equine tetherin cDNA after cloning and sequencing. Both the nucleic acid and the amino acid sequences of the gene were compared to those from cat (GenBank accession number AB564550), human (NM_004335), rhesus macaque (HQ596987), and mouse (NM_198095) (Fig. 1A) . The degrees of sequence identity of equine tetherin with those of cat, human, rhesus macaque, and mouse were 74%, 58%, 57%, and 48% in nucleic acid and 53%, 40%, 36%, and 34% in amino acid, respectively.
Based on bioinformatic prediction (CLUSTALW2, HMMTOP, big-PI Predictor GPI Modification Site Prediction, and NetNGlyc 1.0 Server), a C-terminal GPI anchor, an extracellular coiled-coil domain, and an N-terminal transmembrane domain were identified in equine tetherin. Three cysteine residues in the extracellular domain, which are important for dimer formation, are also conserved in the equine tetherin sequence. In addition, like feline tetherin, equine tetherin has a shorter N-terminal region than human and monkey tetherins, but this structural feature did not affect the protein's tethering function and subcellular localization ( Fig. 2A ; see Fig. 4 ). Thus, equine tetherin has a topology similar to those of other mammalian orthologs.
Tetherin is constitutively expressed in monocyte-derived macrophages and plasmacytoid dendritic cells. To determine how tetherin transcripts are expressed in equine cells permissive for EIAV replication, the levels of tetherin expression in equine macrophages, equine dermal cells, and equine vascular endothelial cells were analyzed by real-time RT-PCR. As a control, we first compared tetherin mRNA expression in human HeLa and HEK 293T cells and found that HeLa cells expressed significantly higher levels of tetherin mRNA than 293T cells (P Ͻ 0.01) (Fig. 1B) . This result is consistent with previous reports by other groups (1, 35) . Next, we compared tetherin expression in equine cells. It was found that high levels of tetherin transcripts were detected in equine macrophages; the levels of tetherin mRNA in equine dermal cells and equine vascular endothelial cells were low, but they were still detectable (P Ͻ 0.01) (Fig. 1C) . Because EIAV is macrophage-tropic, the high level of tetherin expression in equine macrophages and how EIAV overcomes this barrier are of particular interest.
It has been reported that the expression of tetherin is inducible by type I IFNs. To study this mechanism, we analyzed the nucle- otide sequence of equine tetherin's promoter region and the 5= untranslated region (5= UTR) obtained from 5=-RACE analysis. The equine tetherin gene has an 88-bp 5= UTR. Like the other mammalian orthologs, its promoter region contains a putative nontraditional TATA box, a GC box, and several potential transcription factor-binding sites that may bind to NF-AT and STAT ( Fig. 2A) . In addition, at least two IFN-responsive elements, IRF and ISRE, which contain multiple overlapping consensus sequence motifs, were also identified ( Fig. 2A) , To confirm that the expression of equine tetherin is induced by type I IFN, equine macrophages, equine dermal cells, and equine vascular endothelial cells were treated with IFN-␣ for 24 h at 1,000 units/ml, and the levels of tetherin expression were quantified by quantitative real-time RT-PCR. It was found that, as in human HeLa cells, Then, tetherin and ␤-actin mRNA expression levels were quantified by real-time PCR. The numbers of tetherin mRNA copies were normalized to those of ␤-actin. The data represent the means and SD for three independent experiments. A P value of Ͻ0.01 was considered very significant. IFN-␣ could significantly increase tetherin expression in all these equine cells (P Ͻ 0.01). However, the levels of increase (about 6-fold) were slightly higher in equine macrophages and equine dermal cells than in equine vascular endothelial cells (about 2-fold) (Fig. 2B) . Altogether, these results confirmed that the expression of equine tetherin is also inducible by IFN-␣.
Equine tetherin inhibits lentivirus release. Since a high level of equine tetherin expression was observed in macrophages (Fig.  1C) , we next asked if tetherin inhibits EIAV replication in macrophages. When we transfected equine macrophages with an equine-tetherin-specific small interfering RNA (siRNA), equine tetherin mRNA expression was significantly decreased compared to the relatively high level of equine tetherin expression in untreated cells or cells transfected with control siRNA (P Ͻ 0.01) (Fig. 3A) . EIAV (1 ϫ 10 3 50% tissue culture infective doses [TCID 50 ]) was used to infect these macrophages, and viral replication was monitored by detecting viral reverse transcriptase in the supernatant. Increased EIAV replication was observed in the tetherin knockdown cells compared with the untreated and treated with control siRNA groups (Fig. 3B ). This result indicated that equine tetherin may have the ability to block EIAV replication.
To determine whether equine tetherin blocks EIAV VLP release, an EIAV Gag Pol expression vector was transfected into HEK 293T cells in the presence of an equine, human, or macaque tetherin expression vector. After 48 h, VLPs were isolated from the supernatants, and Gag expression in VLPs and cells was analyzed by Western blotting. It was found that in the presence of a huTHN, a macTHN, or an eqTHN, no VLPs were detected in the supernatants (Fig. 3C) , while tetherin did not affect viral Gag protein expression in the cells. It was confirmed that this effect of eqTHN was dose dependent (Fig. 3D) . Thus, like huTHN and macTHN, eqTHN could strongly block EIAV VLP release.
Next, we determined whether equine tetherin could inhibit SIV or HIV particle release. To measure HIV-1 and SIV release, 293T cells were transfected with an HIV-1 or SIVmac239 (⌬Env ⌬Nef) proviral construct in the presence of huTHN, macTHN, or eqTHN. After 48 h, VLPs were purified from cell supernatants and the viral particles released were analyzed. It was found that huTHN blocked SIV but not HIV-1 release, which is consistent with the fact that HIV-1 Vpu can neutralize huTHN; macTHN blocked HIV-1 VLP release, which is consistent with the fact that HIV-1 Vpu cannot neutralize macTHN ( Fig. 3E and F) ; macTHN also inhibited SIV VLP release in the absence of Env and Nef (Fig.  3F) . Notably, eqTHN could block both HIV-1 and SIV release, indicating that eqTHN has very broad antiviral activity and that HIV-1 cannot counteract this equine restriction factor. Subcellular localization of equine tetherin. To understand how equine tetherin blocks viral release, we determined whether it could retain EIAV VLPs on the cell surface. HEK 293T cells were transfected with a human (Fig. 4A ) or an equine (Fig. 4B ) tetherin expression vector in the presence or absence of an EIAV Gag Pol expression vector, and Gag and tetherin subcellular distribution was determined by fluorescence microscopy. Most of the human and equine tetherins were found on the cell surface ( Fig. 4A and B , rows 1), and the EIAV Gag proteins were found in the cytoplasm when they were transfected individually ( Fig. 4A and B, rows 2) . However, when tetherin and Gag proteins were expressed together, the EIAV Gag proteins were colocalized on the plasma membrane with human or equine tetherin (Fig. 4A and B, rows 3 ).
Taken together, these results further confirmed that equine tetherin could inhibit the release of EIAV particles from 293T cells, likely by tethering nascent virus particles on the cell surface.
Mapping of the active antiviral domain of equine tetherin. N-linked glycosylation sites of feline tetherin were shown to be important for its antiviral activity (14) . We next asked if equine tetherin has a similar phenotype. Single or double mutations in the N-linked glycosylation sites (N51A, N79A, and N51A/N78A) were created and used to transfect 293T cells, together with the EIAV Gag Pol construct. We found that in fact it was not required for tetherin function (Fig. 5A) . Both CT and GPI play important roles in maintaining tetherin's function. To dissect the roles of these two domains of equine tetherin in its antiviral capability, two equine tetherin mutants were created, which contained a deletion of the cytoplasmic tail (delCT) and GPI (delGPI), respectively. They were transfected with the EIAV Gag Pol expression vector into 293T cells, and after 48 h, viral release was measured. It was found that both delCT and delGPI showed slight molecular weight changes in Western blotting. The wild-type tetherin protein markedly decreased the viral particle production, and in contrast, the delGPI mutant almost completely lost its antiviral activity. The inhibitory activity of delCT was significantly reduced (Fig.  5B) . Notably, the subcellular distribution of delCT, but not del-GPI, was partially changed to the cytoplasmic compartment (Fig.  5C ). Unlike human tetherin reported previously (1), delCT was 293T cells were transfected with an HA-tagged human tetherin expression construct (A) or an HA-tagged equine tetherin construct (B) and an EIAV Gag Pol expression construct. Twenty-four hours later, the cells were stained with an anti-HA antibody (green) and an anti-EIAV antibody (red), and nuclei were stained with DAPI (blue). Then, the cells were analyzed by confocal microscopy. Single deconvolved optical sections acquired at the cell-coverslip interface are shown.
well glycosylated (Fig. 5D) . Thus, the cytoplasmic tail and GPI anchor, but not the glycosylation domain, are critical for equine tetherin antiviral activity. Equine tetherin can be neutralized by EIAV Env protein, but not HIV-1 Vpu. Lentiviruses have evolved various mechanisms to counteract tetherin restriction. For example, the antiviral activity of tetherin could be neutralized by several viral proteins, including Vpu of HIV-1, Nef of SIV, and the envelope proteins of HIV-2, SIVtan, and FIV. To understand how EIAV evades this host restriction, we tested whether any viral proteins could neutralize equine tetherin activity. First, we directly measured HIV-1 Vpu activity against equine tetherin. A Vpu expression construct was transfected into 293T cells along with the EIAV Gag Pol expression vector and the expression vector for human or equine tetherin, and viral release was determined. It was found that HIV-1 Vpu could overcome the human tetherin but not the equine tetherin inhibitory activity (Fig. 6A) , which further confirmed our previous observation (Fig. 3C, E, and F) . Thus, the activity of Vpu against tetherin is species specific. Second, we directly tested the activities of the EIAV S2, Rev, and Env proteins. An S2, Rev, or Env expression vector was transfected into 293T cells, along with the EIAV Gag Pol expression vector plus the expression vector for human or equine tetherin, and viral release was determined. It was found that neither S2 nor Rev could counteract equine tetherin antiviral activity ( Fig. 6B and C) . However, expression of the EIAV Env protein almost completely overcomes the antiviral activity of equine tetherin, but not human tetherin (Fig. 6D) . Increasing the doses of Env expression proportionally rescued the release of VLPs (Fig. 6E) . Similar results were found when we transfected equine dermal cells (data not shown).
To confirm this finding, we determined how EIAV Env interacts with equine and human tetherins by a GST pulldown assay. Equine or human tetherin was fused with a GST tag, and these fusion proteins were coexpressed with EIAV Env proteins. Cellular proteins were pulled down by glutathione-agarose beads, and the bead-associated proteins were analyzed by Western blotting. It was found that the Env protein was copurified with equine, but not human, tetherin, indicating that EIAV Env specifically interacts with equine tetherin (Fig. 7A) . To further confirm this specific interaction, we determined how EIAV Env affects equine tetherin subcellular localization. 293T cells were transfected with Env and tetherin expression vectors, and their subcellular distribution was determined by confocal microscopy. It was found that upon expression of EIAV Env, equine tetherin was redistributed from the cell surface to intracellular compartments, where the proteins were colocalized (Fig. 7B) . Next, we asked whether EIAV Env could degrade the equine tetherin. Using increasing amounts of Vpu or Env expression plasmids, we found that Vpu could specifically degrade huTHN, but not eqTHN, in a dose-dependent manner (Fig. 7C) . EIAV Env protein could not degrade huTHN and eqTHN (Fig. 7D) , although it was able to bind to eqTHN specifically (Fig. 7A) , indicating that a different mechanism may be used by EIAV Env to counteract eqTHN. Taken together, these results revealed that EIAV Env could specifically counteract equine tetherin antiviral activity.
DISCUSSION
Retroviruses are subject to a variety of host restrictions, which are created by a number of different cellular restriction factors. These factors inhibit viral replication at different steps of the viral life cycle, which represents a new layer of innate immunity to protect hosts from retroviral infection (36, 37) . In the case of HIV-1, viral replication can be inhibited by many cellular proteins, such as APOBEC3, TRIM5␣, tetherin, SAMHD1, and MOV10 (36) . EIAV is a member of the lentiviruses, with the simplest genome structure within the family. EIAV infection is used as a model for the study of the immunology and pathology of lentiviruses and as an efficient delivery system for gene therapy (38, 39) . So far, equine APOBEC is the only equine restriction factor that has been characterized (40, 41) . Here, we demonstrate that equine tetherin is expressed in equine macrophages, fibroblasts, and other equine cell types and is able to inhibit the release of EIAV from transfected 293T cells in vitro as potently as human tetherin.
The discovery of tetherin antiviral activity has provided a new strategy for inhibition of enveloped virus replication. This novel antiviral mechanism needs to be further studied at the molecular level. Human tetherin has broad activity against a wide variety of viruses. Our data also showed that equine tetherin inhibits the release of several lentivirus particles from cells, including HIV, SIV, and EIAV. These findings indicated that tetherins derived from different species share similar components to interact with retroviruses. The evidence that tetherin colocalized with viral particles at the plasma membrane also supports this hypothesis. However, it is still unclear how tetherin retains virions on cell membranes.
A number of studies have shown that the unusual molecular topology of tetherin plays an important role in its biological function (23, 42) . A dual-tyrosine motif (Y 6 -Y 8 ) in the cytoplasmic domain of human tetherin is crucial for trafficking between lipid rafts on the plasma membrane and intracellular compartments, including the trans-Golgi Network (TGN), via adaptor complexes involved in clathrin-mediated endocytosis (43) (44) (45) . We have found that equine tetherin bears a cytoplasmic N-terminal region, a transmembrane region, an ectodomain, and a C-terminal GPI anchor. Interestingly, its cytoplasmic tail lacks 16 amino acids compared with human tetherin, sharing similarity with feline tetherin (14, 16) . Equine tetherin carries a shorter N-terminal region but displays strong inhibition of viral particle release. Interestingly, murine tetherin has a single-nucleotide polymorphism that mutated the first ATG, which was expressed at a higher level and showed more potent inhibition of Friend retrovirus release (17) . There is also evidence that a shorter isoform of ovine tetherin displays stronger antiviral activity than that found in the longer one (11) . Thus, the short forms of tetherins do not have a dual-tyrosine motif in their cytoplasmic domains, so we hypothesize that they may be internalized via a different pathway. It is not clear how these features affect the antiviral activity. It is apparent that the selective pressure from viruses has led to species specificity and diversity in restriction factors. The loss of the N-terminal region of tetherin in some species reflects a coevolution relationship between host and virus, and its significance needs to be further evaluated.
It has been reported that the GPI anchor-mediated localization to lipid rafts promoted clathrin-mediated endocytosis. The GPI anchor is crucial for the antiviral activity of tetherin (1, 46, 47) . We also found that removal of the GPI anchor of equine tetherin abolished its antiviral function, while unlike human tetherin, deletion of CT in equine tetherin showed a partial impact on its antiviral activity, indicating a different function of the CT domain. In addition, we checked whether the two sites for posttranslational N-linked glycosylation were important for antiviral activity. In agreement with previous studies (5, 48), we found that introduc- tion of mutations to the N-linked glycosylation sites had no effect on tetherin antiviral activity, although it had been reported that glycosylation of feline tetherin is crucial for tetherin to block virus release (14) . Since the localization of glycosylation sites differs between species, whether the localization of glycosylation affects the antiviral function remains unknown. Many viruses have evolved their own strategies to overcome restriction by tetherin. Among the primate lentiviruses, the Vpu protein of HIV-1 and the envelope glycoprotein of HIV-2 antagonize human tetherin, while most SIVs use Nef to antagonize the tetherin in the nonhuman primate hosts (27, 29, 30, 49, 50) . Additional viral antagonists of tetherin include the KSHV K5 protein and the glycoproteins of SIV, FIV, and Ebola virus (2, 4, 16, 31, 32) . The activities of these viral proteins as tetherin antagonists are species specific (51, 52) . The mechanism by which HIV-1 Vpu counteracts human tetherin has been extensively studied. The major Vpu-responsive site in tetherin was mapped to an STS motif (positions 3 to 5) within the cytoplasmic tail, which is required for Vpu/␤-TrCP-dependent ubiquitination (53) . The EIAV genome does not carry a Vpu-or Nef-encoding sequence. However, like the HIV-1 Vpu protein, the EIAV S2 protein is also encoded by an open reading frame that overlaps with env, and its translation is also regulated by leaky ribosome scanning (54, 55) . Thus, the HIV-1 vpu and EIAV S2 genes have very similar genomic localizations and share very similar expression strategies, indicating that they may have similar functions. Nevertheless, we found that EIAV S2 could not counteract the equine tetherin activity, indicating that EIAV S2 and HIV-1 Vpu may not necessarily have similar functions. The previous study showed that the EIAV S2 mutants replicated similarly to those of the parental virus in equine cell cultures, including macrophages, indicating that the S2 gene is dispensable for viral replication in vitro (56) . Interestingly, we found that EIAV envelope protein can rescue EIAV VLP budding from the cell by interacting with equine tetherin, sharing similar phenotypes of interaction between FIV envelope and feline tetherin. Unlike HIV-1 Vpu, the EIAV Env protein could not degrade tetherin. Although EIAV Env, like Ebola virus glycoprotein (57) , could bind to tetherin and sequestrate in the intracellular compartment, the details of how envelope proteins antagonize tetherin remain unknown.
In summary, studies on retrovirus restriction by tetherin in horses provide another useful opportunity to further understand the interaction between intrinsic immunity and retroviral infection. We will continue to study the role of tetherin in defending against EIAV infection in vivo and how EIAV Env counteracts this restriction to establish persistent infection.
